Trotabresib

Phase 1Small molecule

NNorthwestern University

Trotabresib is one of 26 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leptomeningeal MetastasisActive, not recruiting

Leptomeningeal MetastasisPhase 1

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Leptomeningeal Metastasis

#DrugCompanyPhaseTrials

Cytosar

Lenvima

Trexall

Alnylam Pharmaceuticals

Approved

—4

Intrathecal Chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Approved

1 5

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 2

10 6

Folvite

Eli Lilly

Phase 2

1 7

Beyfortus

Keytruda

Decadron

AAspen Global Incorporated

Phase 2

2 10

Intrathecal Methotrexate

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leptomeningeal Metastasis1 trial

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Withdrawn·NNorthwestern University·Phase 1·NCT06137651

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trotabresib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trotabresib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trotabresib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNorthwestern University

Trotabresib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leptomeningeal Metastasis1 trial

References

Drug Info

Quick Facts

Related News